New pill targets heart risk by lowering inflammation – first human trial begins
NCT ID NCT07119125
First seen Oct 31, 2025 · Last updated Jun 17, 2026 · Updated 34 times
Summary
This study tests an experimental drug called MRT-8102 for the first time in humans. It includes healthy volunteers and people with high inflammation (elevated CRP) who are at risk for heart problems. The goal is to check the drug's safety and find the right dose for future studies. Participants receive either the drug or a placebo by mouth for up to 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Pharmacology of Miami, LLC
Miami, Florida, 33172, United States
-
Endeavor Clinical Trials
San Antonio, Texas, 78240, United States
-
ICON Clinical Research
Lenexa, Kansas, 66219, United States
-
QPS
Springfield, Missouri, 65807, United States
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.